ClinicalTrials.Veeva

Menu

N-acetylcysteine in Bulimia Nervosa

L

Lindner Center of HOPE

Status and phase

Terminated
Phase 3
Phase 2

Conditions

NAC

Treatments

Drug: N-acetylcysteine NAC

Study type

Interventional

Funder types

Other

Identifiers

NCT01131572
IRB19223, 09-09-18-01

Details and patient eligibility

About

This study tests NAC in the treatment of Bulimia Nervosa.

Enrollment

11 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Bulimia Nervosa
  • 18-65 years of age

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

11 participants in 1 patient group

N-acetylcysteine
Other group
Description:
open label treatment. Each subject receives N-acetylcysteine.
Treatment:
Drug: N-acetylcysteine NAC

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems